1)Hayreh SS, Zimmerman B:Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 110:1204-1215, 2003
2)Liu GT, Glaser JS, Schatz NJ et al:Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 101:1779-1785, 1994
3)Vodopivec I, Rizzo JF 3rd:Ophthalmic manifestations of giant cell arteritis. Rheumatology(Oxford)57:ii63-ii72, 2018
4)前久保知行:視神経炎と虚血性視神経症.眼科グラフィック9:456-462,2020
5)Kobayashi S, Yano T, Inaba Y et al:Ocular involvements of Japanese patients with giant cell arteritis from the first nation-wide survey. Arthritis Rheum 49:867-868, 2003
6)Eberhardt RT, Dhadly M:Giant cell arteritis:diagnosis, management, and cardiovascular implications. Cardiol Rev 15:55-61, 2007
7)尾崎承一・安藤太三・居石克夫・他:血管炎症候群の診療ガイドライン[循環器病の診断と治療に関するガイドライン(2006-2007年度合同研究班報告)].Circ J 72:1253-318,2008
8)Ogata A:Why we use tocilizumab in RA. Clin Rheumatol Rel Res 30:192-198, 2018
9)Khanna RK, Hage R, Lecler A et al:Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids:a case report. J Fr Ophtalmol 44:481-484, 2021
10)Ono T, Mito Y, Okamoto N et al:Tocilizumab Therapy Effbctively Treats Arteritic Anterior Ischemic Optic Neuropathy. Clin Ophthalmol 14:775-793, 2020
11)Stone JH, Tuckwell K, Dimonaco S et al:Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377:317-328, 2017